Synthesis and Characterization of Glucopyranosyloxyphenylacetamide: ADMET and PASS Evaluation as a Prodrug Analog

Md. Ansarul Islam; Mahbub Alam; Emranul Kabir; Md. Abdul Hai; Md. Mosharef Hossain Bhuiyan

doi:10.30872/jtpc.v10i1.375

Authors

Md. Ansarul Islam Department of Chemistry, Faculty of Science Jahangirnagar University, Savar, Dhaka – 1342, Bangladesh Author
Mahbub Alam Department of Chemistry, Bangladesh Army University of Science and Technology Khulna, Khulna 9204, Bangladesh Author https://orcid.org/0000-0001-8978-4160
Emranul Kabir Department of Chemistry, Faculty of Science University of Chittagong, Chattogram 4331, Bangladesh Author https://orcid.org/0000-0001-5444-5732
Md. Abdul Hai Department of Chemistry, Faculty of Science, Jahangirnagar University, Savar, Dhaka – 1342, Bangladesh Author
Md. Mosharef Hossain Bhuiyan Department of Chemistry, Faculty of Science, University of Chittagong, Chattogram-4331, Bangladesh Author

DOI:

https://doi.org/10.30872/jtpc.v10i1.375

Keywords:

Prodrugs, Glucopyranosyloxyphenylacetamide, ADMET, PASS

Abstract

This study investigates the manufacturing of glycoside-based derivatives of drugs, and their applications to produce injectable medications for colds and flu that alleviate problems with low solubility in water. Regarding these perspectives, this research was designed to prepare 4-o-β-D-glucopyranosyloxyphenylacetamide (7) through multistep synthesis, which was characterized through FT-IR spectra, ¹H NMR, ¹³C NMR, and melting point analysis, comparing it with the reported compound (8). ADMET and PASS of the synthesized compound were performed to assess the compounds' pharmacokinetics, toxicological profiles, and biological activities, i.e., low carcinogenicity, AOT category III, and antiviral potentiality etc.

Downloads

Download data is not yet available.

References

[1] P. R. Ram, P. Priyanka, L. Shreekrishna, and S. Saroj, “Prodrug as a novel approach of drug delivery—a review,” J. Drug Deliv. Ther., vol. 5, no. 3, pp. 5–9, 2015, doi: 10.22270/JDDT.V5I3.1140.

[2] Y. Hamada, “Recent progress in prodrug design strategies based on generally applicable modifications,” Bioorg. Med. Chem. Lett., vol. 27, no. 8, pp. 1627–1632, 2017, doi: 10.1016/j.bmcl.2017.02.075.

[3] M. Markovic, S. Ben-Shabat, and A. Dahan, “Prodrugs for improved drug delivery: Lessons learned from recently developed and marketed products,” Pharmaceutics, vol. 12, no. 11, p. 1031, 2020, doi: 10.3390/pharmaceutics12111031.

[4] V. J. Stella, “Prodrugs as therapeutics,” Expert Opin. Ther. Pat., vol. 14, no. 3, pp. 277–280, 2004, doi: 10.1517/13543776.14.3.277.

[5] A. Dahan, M. Khamis, R. Agbaria, and R. Karaman, “Targeted prodrugs in oral drug delivery: The modern molecular biopharmaceutical approach,” Expert Opin. Drug Deliv., vol. 9, no. 8, pp. 1001–1013, 2012, doi: 10.1517/17425247.2012.697055.

[6] A. Dahan, E. M. Zimmermann, and S. Ben-Shabat, “Modern prodrug design for targeted oral drug delivery,” Molecules, vol. 19, no. 10, pp. 16489–16505, 2014, doi: 10.3390/molecules191016489.

[7] A. Dahan, M. Markovic, A. Aponick, E. M. Zimmermann, and S. Ben-Shabat, “The prospects of lipidic prodrugs: An old approach with an emerging future,” Future Med. Chem., vol. 11, no. 19, pp. 2563–2571, 2019, doi: 10.4155/fmc-2019-0155.

[8] M. Markovic et al., “Lipidic prodrug approach for improved oral drug delivery and therapy,” Med. Res. Rev., vol. 39, no. 2, pp. 579–607, 2019, doi: 10.1002/med.21533.

[9] M. Markovic et al., “Lipids and lipid-processing pathways in drug delivery and therapeutics,” Int. J. Mol. Sci., vol. 21, no. 9, p. 3248, 2020, doi: 10.3390/ijms21093248.

[10] A. T. Metaib et al., “The production and estimation of diclofenac amide prodrug,” J. Pharm. Negat. Results, vol. 13, no. 3, pp. 218–222, 2022, doi: 10.47750/pnr.2022.13.03.114.

[11] S. Mishra, S. Tripathi, and K. Misra, “Synthesis of a novel anticancer prodrug designed to target telomerase sequence,” in Nucleic Acids Symp. Ser., vol. 2, no. 1, pp. 277–278, 2002, doi: 10.1093/nass/2.1.277.

[12] H. S. P. Rao, “Capping drugs: Development of prodrugs,” Resonance, vol. 8, pp. 19–27, 2003, doi: 10.1007/BF02835647.

[13] C. J. Briscoe and D. S. Hage, “Factors affecting the stability of drugs and drug metabolites in biological matrices,” Bioanalysis, vol. 1, no. 1, pp. 205–220, 2009, doi: 10.4155/bio.09.20.

[14] K. Beaumont et al., “Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist,” Curr. Drug Metab., vol. 4, no. 6, pp. 461–485, 2003, doi: 10.2174/1389200033489253.

[15] D. Jappar, Y. Hu, and D. E. Smith, “Effect of dose escalation on the in vivo oral absorption and disposition of glycylsarcosine in wild-type and Pept1 knockout mice,” Drug Metab. Dispos., vol. 39, no. 12, pp. 2250–2257, 2011, doi: 10.1124/dmd.111.041087.

[16] D. Jappar et al., “Significance and regional dependency of peptide transporter (PEPT1) in the intestinal permeability of glycylsarcosine,” Drug Metab. Dispos., vol. 38, no. 10, pp. 1740–1746, 2010, doi: 10.1124/dmd.110.034025.

[17] F. Sodano et al., “Paracetamol–galactose conjugate: A novel prodrug for an old analgesic drug,” Mol. Pharm., vol. 16, no. 10, pp. 4181–4189, 2019, doi: 10.1021/acs.molpharmaceut.9b00508.

[18] A. L. Simplício, J. M. Clancy, and J. F. Gilmer, “Prodrugs for amines,” Molecules, vol. 13, no. 3, pp. 519–547, 2008, doi: 10.3390/molecules13030519.

[19] M. D. Basson, L. Panzini, and R. Palmer, “Effect of nabumetone and aspirin on colonic mucosal bleeding time,” Aliment. Pharmacol. Ther., vol. 15, no. 4, pp. 539–542, 2001, doi: 10.1046/j.1365-2036.2001.00948.x.

[20] D. M. Avhad et al., “Synthesis and evaluation of mutual prodrugs of ibuprofen as NSAIDs with antioxidants,” World J. Pharm. Pharm. Sci., vol. 9, no. 5, pp. 1426–1438, 2020.

[21] W. Fan et al., “Design, synthesis and biological evaluation of brain-specific glucosyl thiamine disulfide prodrugs of naproxen,” Eur. J. Med. Chem., vol. 46, no. 9, pp. 3651–3661, 2011, doi: 10.1016/j.ejmech.2011.05.029.

[22] E. G. Ma et al., “Three new phenylacetamide glycosides from Dracocephalum tanguticum and their anti-hyperglycemic activity,” Nat. Prod. Res., vol. 34, no. 13, pp. 1827–1835, 2020, doi: 10.1080/14786419.2018.1562451.

[23] R. M. Silverstein and G. C. Bassler, “Spectrometric identification of organic compounds,” J. Chem. Educ., vol. 39, no. 11, p. 546, 1962, doi: 10.1021/ed039p546.

[24] V. J. Stella and K. W. Nti-Addae, “Prodrug strategies to overcome poor water solubility,” Adv. Drug Deliv. Rev., vol. 59, no. 7, pp. 677–694, 2007, doi: 10.1016/j.addr.2007.05.013.

[25] F. Sodano et al., “Galactosylated prodrugs: A strategy to improve the profile of nonsteroidal anti-inflammatory drugs,” Pharmaceuticals, vol. 15, no. 5, p. 552, 2022, doi: 10.3390/ph15050552.

[26] A. Aliabadi et al., “2-(4-Fluorophenyl)-N-phenylacetamide derivatives as anticancer agents,” Iran. J. Pharm. Res., vol. 12, no. 3, p. 267, 2013, doi: 10.22037/ijpr.2013.1326.

[27] G. Celik, “New chalcone-3-O-glycoside derivatives: Synthesis and characterization,” J. Chem. Res., vol. 44, no. 9–10, pp. 598–601, 2020, doi: 10.1177/174751982091516.

[28] M. K. Hasan et al., “Selective modification of diclofenac to reduce adverse effects,” Inform. Med. Unlocked, vol. 36, p. 101159, 2023, doi: 10.1016/j.imu.2023.101159.

[29] V. N. Ingle, S. T. Kharche, and U. G. Upadhyay, “Glucosylation of 4′-hydroxychalcones using glucosyl donor,” Indian J. Chem. B, vol. 44, no. 4, pp. 801–805, 2005.

[30] J. Dong et al., “ADMETlab: A platform for systematic ADMET evaluation,” J. Cheminform., vol. 10, pp. 1–11, 2018, doi: 10.1021/ci300367a.

[31] A. M. Davis and R. J. Riley, “Predictive ADMET studies: The challenges and opportunities,” Curr. Opin. Chem. Biol., vol. 8, no. 4, pp. 378–386, 2004, doi: 10.1016/j.cbpa.2004.06.005.

[32] G. Xiong et al., “ADMETlab 2.0: An integrated online platform,” Nucleic Acids Res., vol. 49, no. W1, pp. W5–W14, 2021, doi: 10.1021/ci300367a.

[33] Y. Gu et al., “admetSAR 3.0: A comprehensive platform for ADMET prediction,” Nucleic Acids Res., vol. 52, no. W1, pp. W432–W438, 2024, doi: 10.1021/jm020017n.

[34] I. Hubatsch, E. G. Ragnarsson, and P. Artursson, “Determination of drug permeability in Caco-2 monolayers,” Nat. Protoc., vol. 2, no. 9, pp. 2111–2119, 2007, doi: 10.1038/nprot.2007.303.

[35] M. L. Amin, “P-glycoprotein inhibition for optimal drug delivery,” Drug Target Insights, vol. 7, 2013, doi: 10.4137/DTI.S12519.

[36] S. M. Lamothe et al., “The human ether-à-go-go-related gene (hERG) potassium channel,” J. Biol. Chem., vol. 291, no. 39, pp. 20387–20401, 2016, doi: 10.1074/jbc.M116.743138.

[37] R. Azhaguraj et al., “Prediction of biological activity of algal antitumor drugs using PASS,” Pharmacologyonline, vol. 3, pp. 22–34, 2010.

[38] J. Rautio et al., “The expanding role of prodrugs in contemporary drug design,” Nat. Rev. Drug Discov., vol. 17, no. 8, pp. 559–587, 2018, doi: 10.1038/nrd.2018.46.

[39] B. Testa and J. M. Mayer, Hydrolysis in Drug and Prodrug Metabolism. Hoboken, NJ, USA: Wiley, 2003.

[40] A. Lagunin et al., “PASS: Prediction of activity spectra for biologically active substances,” Bioinformatics, vol. 16, no. 8, pp. 747–748, 2000, doi: 10.1093/bioinformatics/16.8.747.